vs
Side-by-side financial comparison of Creative Media & Community Trust Corp (CMCT) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Creative Media & Community Trust Corp is the larger business by last-quarter revenue ($28.5M vs $20.4M, roughly 1.4× Sight Sciences, Inc.). Sight Sciences, Inc. runs the higher net margin — -20.4% vs -125.8%, a 105.3% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs 3.6%). Over the past eight quarters, Sight Sciences, Inc.'s revenue compounded faster (2.9% CAGR vs -8.5%).
Creative Media & Community Trust Corp is a U.S.-headquartered real estate investment trust operating two core segments: it owns, manages and develops creative media facilities including professional film and TV production studios, plus community-focused assets such as affordable housing, neighborhood healthcare centers and local commercial spaces, serving media operators and local communities nationwide.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
CMCT vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.5M | $20.4M |
| Net Profit | $-11.4M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | -125.6% | -18.0% |
| Net Margin | -125.8% | -20.4% |
| Revenue YoY | 3.6% | 6.9% |
| Net Profit YoY | -11.4% | 64.9% |
| EPS (diluted) | $-3.89 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $28.5M | $20.4M | ||
| Q3 25 | $26.2M | $19.9M | ||
| Q2 25 | $29.7M | $19.6M | ||
| Q1 25 | $32.3M | $17.5M | ||
| Q4 24 | $27.5M | $19.1M | ||
| Q3 24 | $28.6M | $20.2M | ||
| Q2 24 | $34.4M | $21.4M | ||
| Q1 24 | $34.0M | $19.3M |
| Q4 25 | $-11.4M | $-4.2M | ||
| Q3 25 | $-12.5M | $-8.2M | ||
| Q2 25 | $-9.0M | $-11.9M | ||
| Q1 25 | $-6.1M | $-14.2M | ||
| Q4 24 | $-10.3M | $-11.8M | ||
| Q3 24 | $-10.4M | $-11.1M | ||
| Q2 24 | $-796.0K | $-12.3M | ||
| Q1 24 | $-3.7M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | -125.6% | -18.0% | ||
| Q3 25 | -47.7% | -39.7% | ||
| Q2 25 | -30.3% | -59.6% | ||
| Q1 25 | -19.0% | -79.2% | ||
| Q4 24 | -128.8% | -62.5% | ||
| Q3 24 | -36.9% | -55.7% | ||
| Q2 24 | -1.6% | -59.2% | ||
| Q1 24 | -10.7% | -76.4% |
| Q4 25 | -125.8% | -20.4% | ||
| Q3 25 | -47.5% | -41.0% | ||
| Q2 25 | -30.3% | -61.0% | ||
| Q1 25 | -18.9% | -80.8% | ||
| Q4 24 | -129.8% | -62.1% | ||
| Q3 24 | -36.3% | -54.9% | ||
| Q2 24 | -2.3% | -57.7% | ||
| Q1 24 | -11.0% | -84.4% |
| Q4 25 | $-3.89 | $-0.07 | ||
| Q3 25 | $-23.52 | $-0.16 | ||
| Q2 25 | $-18.94 | $-0.23 | ||
| Q1 25 | $-20.73 | $-0.28 | ||
| Q4 24 | $97.71 | $-0.23 | ||
| Q3 24 | $-305.04 | $-0.22 | ||
| Q2 24 | $-98.64 | $-0.25 | ||
| Q1 24 | $-125.46 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.4M | $92.0M |
| Total DebtLower is stronger | $509.8M | $42.4M |
| Stockholders' EquityBook value | $265.4M | $63.9M |
| Total Assets | $859.2M | $115.3M |
| Debt / EquityLower = less leverage | 1.92× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.4M | $92.0M | ||
| Q3 25 | $17.3M | $92.4M | ||
| Q2 25 | $27.8M | $101.5M | ||
| Q1 25 | $19.8M | $108.8M | ||
| Q4 24 | $20.3M | $120.4M | ||
| Q3 24 | $18.5M | $118.6M | ||
| Q2 24 | $29.3M | $118.2M | ||
| Q1 24 | $21.3M | $127.3M |
| Q4 25 | $509.8M | $42.4M | ||
| Q3 25 | $527.8M | $42.4M | ||
| Q2 25 | $535.6M | $42.4M | ||
| Q1 25 | $512.7M | $42.4M | ||
| Q4 24 | $505.7M | $40.0M | ||
| Q3 24 | $478.3M | $37.1M | ||
| Q2 24 | $485.1M | $35.0M | ||
| Q1 24 | $472.8M | $35.0M |
| Q4 25 | $265.4M | $63.9M | ||
| Q3 25 | $281.9M | $64.3M | ||
| Q2 25 | $287.1M | $70.0M | ||
| Q1 25 | $293.0M | $77.6M | ||
| Q4 24 | $304.5M | $87.5M | ||
| Q3 24 | $321.0M | $95.0M | ||
| Q2 24 | $351.1M | $101.6M | ||
| Q1 24 | $369.9M | $109.2M |
| Q4 25 | $859.2M | $115.3M | ||
| Q3 25 | $871.8M | $116.3M | ||
| Q2 25 | $885.0M | $122.0M | ||
| Q1 25 | $882.3M | $129.7M | ||
| Q4 24 | $889.6M | $142.8M | ||
| Q3 24 | $868.0M | $143.6M | ||
| Q2 24 | $891.2M | $149.7M | ||
| Q1 24 | $887.5M | $155.6M |
| Q4 25 | 1.92× | 0.66× | ||
| Q3 25 | 1.87× | 0.66× | ||
| Q2 25 | 1.87× | 0.61× | ||
| Q1 25 | 1.75× | 0.55× | ||
| Q4 24 | 1.66× | 0.46× | ||
| Q3 24 | 1.49× | 0.39× | ||
| Q2 24 | 1.38× | 0.34× | ||
| Q1 24 | 1.28× | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.8M | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.8M | $-1.8M | ||
| Q3 25 | $3.7M | $-8.7M | ||
| Q2 25 | $-2.5M | $-7.5M | ||
| Q1 25 | $1.2M | $-11.6M | ||
| Q4 24 | $17.0M | $-3.5M | ||
| Q3 24 | $10.3M | $362.0K | ||
| Q2 24 | $3.9M | $-9.5M | ||
| Q1 24 | $1.6M | $-9.8M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.9M |
| Q4 25 | — | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -51.4% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMCT
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
